Press Release

On 1 December 2009, Osmetech posted a circular to its shareholders (the ”Circular”) regarding , inter alia, a proposed Placing. Contained within the Circular were certain disclosures regarding holdings in the Company of Dr Kayyem, a director of the Company. The Circular stated:

 

“The exact number of Ordinary Shares that Dr Kayyem will beneficially own as a result of Efficacy's participation in the Placing cannot be completely determined until Efficacy has completed its own internal reporting and will be able to inform Dr Kayyem of his exact beneficial holding in the Company”.

 

Dr Kayyem has now informed the Company that the internal reporting at Efficacy is now complete and Dr Kayyem has subsequently transferred out all of his beneficial holdings in Osmetech previously held with Efficacy. Dr Kayyem has confirmed he holds a beneficial holding in the Company totaling 116,355,087 Ordinary Shares, representing 7.12% of the current issued share capital of the Company, and none of which are now held through Efficacy.

 

For the avoidance of doubt, Dr Kayyem has not bought or sold any Ordinary Shares in the Company since participating in the Placing as described in the Circular.

 

As a result of Dr Kayyem transferring out his beneficial holdings in Osmetech from Efficacy, Efficacy now has a disclosable interest in the Company of 201,915,914 Ordinary Shares, representing 12.36% of the current issued share capital of the Company.

 

The total number of issued Ordinary Shares is 1,633,443,351. Osmetech does not hold any Ordinary Shares in Treasury. Therefore, the total number of voting rights in Osmetech is 1,633,443,351.

 

Unless otherwise sated, all defined terms in this announcement shall have the same meaning as those in the Circular of 01 December 2009.